Completed PHASE4 INTERVENTIONAL NCT00276107

Study Evaluating Prevenar Vaccine in Healthy Infants

An Open-Label Trial of the Immunogenicity and Safety of Prevenar (Pneumococcal 7-Valent Conjugate Vaccine [Diphteria CRM197 Protein Conjugate]) in Healthy Infants at 2, 4 and 6 Months of Age

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Conditions Pneumococcal Infections

Interventions Prevenar

Updated 5 times since 2017 Last updated: Jul 28, 2009 Started: Dec 31, 2004 Completion: Dec 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00276107, this PHASE4 trial focuses on Pneumococcal Infections and remains completed. Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, it has been updated 5 times since 2004, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Dec 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Wyeth is now a wholly owned subsidiary of Pfizer

Data source: Wyeth is now a wholly owned subsidiary of Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.